Supraventricular Tachycardia Management

Initial Treatment

The American College of Cardiology recommends adenosine as the first-line pharmacological agent for acute treatment of hemodynamically stable supraventricular tachycardia, with a success rate of approximately 95% for AVNRT cases and 78-96% for SVT overall 1, 2, 3
The American Heart Association suggests performing vagal maneuvers, such as the Valsalva maneuver or carotid sinus massage, as the immediate first intervention, with a success rate of approximately 28% when switching between techniques 2, 3

The American College of Cardiology recommends alternative AV nodal blockers, such as intravenous diltiazem, verapamil, or beta-blockers, as a Class IIa option, with a conversion rate of 64-98%, but with a slower infusion rate to minimize hypotension 1, 2, 3
The American Heart Association suggests synchronized cardioversion as an indicated treatment when pharmacological therapy fails or is contraindicated in stable patients, with a success rate of 80-98% for SVT termination 1, 2

The American College of Cardiology recommends adenosine as a safe and effective treatment for SVT in pregnant patients, with a Class I recommendation 8, 4
The American Heart Association suggests that adenosine remains the first-line treatment for pediatric patients, with success rates matching adults 7, 4

The American College of Cardiology recommends an initial dose of 6 mg rapid IV push via large proximal vein, followed immediately by 20 mL saline flush, with a possible repeat dose of 12 mg if needed 4
The American Heart Association suggests decreasing the initial dose to 3 mg for patients on dipyridamole or carbamazepine, heart transplant recipients, or central venous administration 4

The American College of Cardiology lists contraindications for adenosine, including second or third-degree AV block, sick sinus syndrome, and asthma (risk of bronchospasm) 4
The American Heart Association warns against using calcium channel blockers or amiodarone if VT or pre-excited AF is possible, due to the risk of ventricular fibrillation or hemodynamic collapse 1, 2